Adia Med Files Provisional Patent for Breakthrough Regenerative Medical Protocol

Core Insights - ADIA Nutrition, Inc. has filed a provisional patent application for a novel medical protocol aimed at enhancing regenerative outcomes, marking a significant advancement in the field of regenerative medicine [1][2]. Company Overview - ADIA Nutrition, Inc. is based in Winter Park, Florida, and is publicly traded, focusing on advanced healthcare solutions, particularly in stem cell and regenerative products [5]. - The company operates through its lab division, AdiaLabs LLC, and is expanding its offerings to include insurance-billable wound care products [5][6]. Innovation and Intellectual Property - The newly filed provisional patent represents a proprietary protocol that utilizes unique procedural and biological mechanisms not previously explored in clinical practice, positioning the company as a leader in regenerative medicine [2][3]. - Securing this patent is a crucial step for the company to protect its intellectual property and accelerate the development of next-generation health solutions [3]. Strategic Development - The patent pending status allows ADIA to pursue research, partnerships, and commercialization opportunities over the next 12 months while maintaining confidentiality [3]. - The company is actively seeking strategic partnerships and encouraging clinic owners and healthcare practitioners to integrate its regenerative therapies into their practices [4]. Revenue Generation - ADIA generates revenue through service fees, product sales, equity stakes, and billing insurance for healthcare treatments [6]. - The company is also investing in aligned businesses, such as Cement Factory LLC, which focuses on health and wellness [6].